Exact Therapeutics, clinical-stage biopharmaceutical company developing a proprietary ultrasound-mediated technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® significantly amplifies the clinical utility of a wide range of therapeutic agents across a multitude of applications, including oncology (chemotherapy and immunotherapy), neurological conditions, and gene therapy. Exact's primary focus is oncology, followed by CNS. The lead compound is PS101 which is in Phase 1b for liver metastases and a Phase 2 trial in pancreatic cancer is planned for 2H 2024. EXACT Therapeutics was spun out from GE Healthcare in 2012.